USAntibiotics Expands Leadership Team with Appointment of Steven Lutz to Vice President of Strategic Accounts
USAntibiotics , the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Steven Lutz to vice president of strategic accounts.
- USAntibiotics , the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Steven Lutz to vice president of strategic accounts.
- In this role, Lutz oversees the organization’s commercial strategy to drive continued growth and market share in alignment with the company’s business objectives.
- “Steven’s proven success in driving strategic growth in the pharmaceutical market makes him a great addition to our team,” said Patrick Cashman, president, USAntibiotics.
- We are delighted to welcome Steven to USAntibiotics and our executive leadership team.”
Before joining USAntibiotics, Lutz was on the leadership team at Neos Therapeutics.